Targeted therapy for renal cell cancer: current perspectives

Area of Science:

• Oncology
• Pharmacology

Background:

• Metastatic renal cell cancer (mRCC) is a chemoresistant disease.
• Targeted therapies have recently revolutionized mRCC patient outcomes.
• Vascular Endothelial Growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) signaling pathways are key in mRCC pathogenesis.

Purpose of the Study:

• To review currently approved targeted drugs for metastatic renal cell cancer (mRCC).
• To discuss the role of these targeted agents in the contemporary management of mRCC.

Main Methods:

• Literature review of approved targeted therapies for mRCC.
• Description of anti-VEGF agents (bevacizumab) and receptor tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib).
• Description of mTOR inhibitors (temsirolimus, everolimus).

Main Results:

• Targeted therapies, particularly VEGF and mTOR inhibitors, have significantly improved outcomes for mRCC patients.
• Several targeted drugs are approved for mRCC treatment, including bevacizumab, sunitinib, sorafenib, pazopanib, temsirolimus, and everolimus.

Conclusions:

• Targeted therapy has become a cornerstone in managing metastatic renal cell cancer.
• Approved VEGF and mTOR inhibitors offer significant therapeutic advancements for patients with this challenging disease.